文献速递类风湿关节炎

在早期类风湿关节炎中比较初始甲氨蝶呤单药治疗与初始肿瘤坏死因子抑制剂(阿达木单抗)联合甲氨蝶呤治疗的达标治疗结局

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2017-11-16

OPTIMA研究的事后分析纳入病程<1年、未用过甲氨蝶呤的活动性类风湿关节炎患者,比较初始阿达木单抗+甲氨蝶呤(n=466)与初始甲氨蝶呤单药(n=460)的达标治疗结局。第26周时,初始联合治疗组在临床、功能和影像学结局上达标比例均显著更高。第26至78周,甲氨蝶呤应答不足后加用阿达木单抗补救治疗的患者,其临床和功能结局与初始联合治疗组相似,但初始联合治疗组在第52和78周无影像学进展的比例显著更高。

要点

  • 第26周,初始阿达木单抗+甲氨蝶呤组临床达标53%、功能达标45%、影像学达标87%,均显著高于初始甲氨蝶呤单药组的30%、33%、72%。
  • 第26至78周,甲氨蝶呤补救加用阿达木单抗的患者临床和功能结局与初始联合治疗组相似。
  • 第52和78周,初始联合治疗组无影像学进展比例均为86%,显著高于初始甲氨蝶呤单药组的72%。

核心结论

  • 在早期类风湿关节炎中,先以甲氨蝶呤单药治疗、26周应答不足后再加用肿瘤坏死因子抑制剂,可获得与初始肿瘤坏死因子抑制剂联合甲氨蝶呤相似的长期临床结果,但会带来小而显著的影像学损伤累积。

研究设计与样本

  • OPTIMA研究的事后分析,纳入病程<1年、未用过甲氨蝶呤的活动性类风湿关节炎患者,按初始治疗分层比较第26、52和78周的达标情况。

主要发现

  • 第26周,初始阿达木单抗+甲氨蝶呤组(n=466)与初始甲氨蝶呤单药组(n=460)达到良好临床结局的比例分别为53%与30%,功能结局分别为45%与33%,影像学结局分别为87%与72%,初始联合治疗组均显著更高。
  • 第26至78周,甲氨蝶呤应答不足后加用阿达木单抗补救治疗的患者,其临床和功能结局与初始阿达木单抗+甲氨蝶呤组相似。
  • 第52和78周,初始阿达木单抗+甲氨蝶呤组无影像学进展的比例均为86%,显著高于初始甲氨蝶呤单药组的72%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare responses in patients with early rheumatoid arthritis (RA) initially treated with the tumour necrosis factor inhibitor (TNFi) adalimumab+methotrexate (MTX) versus MTX monotherapy who may have continued receiving MTX or switched to adalimumab rescue therapy after inadequate response to MTX. METHODS: OPTIMA enrolled MTX-naive patients with active RA for <1 year. This post hoc analysis determined the proportion of patients, stratified by initial treatment, who achieved 28-joint modified Disease Activity Score based on C reactive protein <3.2, normal function and/or no radiographic progression at weeks 26, 52 and 78. RESULTS: Significantly greater proportions of patients initially treated with adalimumab+MTX (n=466) compared with MTX monotherapy (n=460) achieved good clinical (53% vs 30%), functional (45% vs 33%) and radiographic (87% vs 72%) outcomes at week 26. From weeks 26 to 78, adalimumab rescue patients achieved similar clinical and functional outcomes versus patients initially treated with adalimumab+MTX. However, significantly more patients initially treated with adalimumab+MTX had no radiographic progression at weeks 52 and 78 versus patients initially treated with MTX (both timepoints: 86% vs 72%). CONCLUSIONS: In early RA, starting with MTX monotherapy and adding TNFi after 26 weeks yields similar longer term clinical results as starting with TNFi+MTX combination therapy but allows a small but significant accrual of radiographic damage.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kavanaugh A, van Vollenhoven RF, Fleischmann R, et al. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 29146743. doi:10.1136/annrheumdis-2017-211871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。